SCHEMBL790696

SCHEMBL790696

C=CCOc1c(CC=C)cc(O)c(CC=C)c1CC=C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 5/20 0.41
GABRB2 P47870 5/20 0.41
POLB P06746 2/20 0.36
PTPN1 P18031 3/20 0.35
XDH P47989 2/20 0.35
KDM4E B2RXH2 2/20 0.34
GAA P10253 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
CNR1 P21554 2/20 0.33
CNR2 P34972 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
ALDH2 P05091 1/20 0.33
AKR1B1 P15121 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SRD5A1 P18405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057559 0.81 HSD17B10 (0.33) GABRA1GABRB2POLBGAAMGAM
SCHEMBL7560809 0.79 LMNA (0.43) GABRA1GABRB2PTPN1KDM4EGAA
SCHEMBL1245217 0.77 GABRA1 (0.48) GABRA1GABRB2POLBXDHKDM4E
SCHEMBL20226271 0.77 CA12 (0.33) GABRA1GABRB2POLBPTGS1PTGS2
SCHEMBL3045553 0.76 GABRA1 (0.47) GABRA1GABRB2POLBXDHKDM4E
SCHEMBL1396137 0.75 PTPN1 (0.31) PTPN1MAPTALDH1A1
SCHEMBL11639066 0.74 KDM4E (0.37) POLBKDM4EGAAMEN1MAPT
SCHEMBL20226270 0.74 GABRA1 (0.44) GABRA1GABRB2POLBGAAMEN1
SCHEMBL28719947 0.73 TLR4 (0.33)
SCHEMBL2457764 0.73 GABRA1 (0.44) GABRA1GABRB2POLBXDHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5364946-A Process for the preparation of substituted pentaalkylchromenes LONZA LTD. (CH) 1994-11-15 US claimed
EP-0543345-B1 Substituted pentaalkylchromanes LONZA AG (CH) 1994-09-07 EP claimed
EP-0543346-B1 Method for the preparation of substituted pentaalkylchromenes LONZA AG (CH) 1994-09-07 EP claimed
US-5313007-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-17 US claimed
US-5310953-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-10 US claimed
JP-6065229-A None JP disclosed
JP-6080658-A None JP disclosed
US-20120071692-A1 PROCESS FOR THE PREPARATION OF AROMATIC AMINES BASF SE (DE) 2012-03-22 US disclosed
US-7767855-B2 Method for the continuous production of an amine BASF SE (DE) 2010-08-03 US disclosed
US-20080200726-A1 Method For the Continuous Production of an Amine BASF AKTIENGESELLSCHAFT (DE) 2008-08-21 US disclosed
US-5364946-A Process for the preparation of substituted pentaalkylchromenes LONZA LTD. (CH) 1994-11-15 US disclosed
US-5313007-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-17 US disclosed
US-5313007-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-17 US disclosed
US-5310953-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-10 US disclosed
US-5310953-A Substituted pentaalkylchromans LONZA LTD. (CH) 1994-05-10 US disclosed
US-5304663-A Tetraalkyl-substituted 1,4-benzoquinones as intermediates for tetra- or penta-alkyl substituted 6-hydroxy-chromenes LONZA LTD. (CH) 1994-04-19 US disclosed
JP-H0680658-A PREPARATION OF SUBSTITUTED PENTAALKYLCHROMEN LONZA AG 1994-03-22 JP disclosed
JP-H0665229-A PRODUCTION OF SUBSTITUTED PENTAALKYLCHROMAN LONZA AG 1994-03-08 JP disclosed
EP-0543346-A1 Method for the preparation of substituted pentaalkylchromenes LONZA AG (CH) 1993-05-26 EP disclosed
EP-0543345-A1 Substituted pentaalkylchromanes LONZA AG (CH) 1993-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071692-A1 PROCESS FOR THE PREPARATION OF AROMATIC AMINES ADH1A, ADH5, ADH1C GABRA1 2183/4885GABRB2 3072/4885POLB 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.